NOVO NORDISK A S - 31 Dec 2025 SCHEDULE 13G/A Report for Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)

Filing Manager
NOVO NORDISK A S
Reporting Manager
Novo Nordisk A/S
Security
Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)
Shares outstanding
93,782,327 shares
Disclosed Ownership
7,333,778 shares
Ownership
7.8%
Form type
SCHEDULE 13G/A
Filing time
04 Mar 2026, 16:45:11 UTC
Date of event
31 Dec 2025
Previous filing
21 Oct 2025
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"NOVO NORDISK A S disclosed 7.8% ownership in Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares) on 31 Dec 2025."

Quick Takeaways

  • NOVO NORDISK A S filed SCHEDULE 13G/A for Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares).
  • Disclosed ownership: 7.8%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 21 Oct 2025.
  • Current filing was accepted on 04 Mar 2026, 16:45.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Novo Nordisk A/S 7.8% 7,333,778 7,333,778 0 /s/ Karsten Munk Knudsen Karsten Munk Knudsen, Chief Financial Officer

Sponsored